CCR8/CDw198 recombinant proteins and antibodies

C-C chemokine receptor type 8 (CCR8), also known as CDw198, CKRL1, CMKBR8, or CMKBRL2, is a G protein-coupled receptor mainly expressed on regulatory T cells (Tregs) and some Th2 cells. Its natural ligand is CCL1. CCR8 plays a key role in immune homeostasis and inflammation. Importantly, CCR8 is highly expressed in tumor-infiltrating immunosuppressive Tregs, especially in solid tumors, while its expression in peripheral tissues and blood is very low. This makes CCR8 an attractive target for selectively depleting tumor Tregs and alleviating tumor immunosuppression, offering a more precise approach than conventional CTLA-4 or PD-1 therapies.

Current drug development strategies targeting CCR8 include monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs). CCR8-depleting antibodies can eliminate tumor-infiltrating Tregs via Fc-mediated ADCC, activating effector T cells and enhancing anti-tumor immunity. Several companies are actively developing CCR8-targeted therapies: Gilead Sciences is advancing GS-1811 (formerly JTX-1811), iTeos Therapeutics is developing ITE-915 in combination with PD-1 inhibitors, and Incyte, Compugen, and Innate Pharma are exploring CCR8 antibodies or bispecific candidates in early-stage pipelines. Some groups are also investigating bispecific antibodies targeting CCR8 and PD-1 or CTLA-4 to combine immune activation with selective Treg depletion.

DIMA BIOTECH offers a comprehensive portfolio of CCR8/CDw198 products, including recombinant CCR8 proteins (multi-tag, multiple species, various epitopes), full-length membrane proteins (CCR8 nanodiscs and MNPs), flow cytometry antibodies, biotin/PE-labeled antibodies, and biosimilar reference antibodies. A B cell seed library enables rapid screening of lead antibodies within 20 days, and selected CCR8 leads are available for functional evaluation as early as the next day. These resources support efficient research and development of CCR8-targeted immunotherapies.